The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Evidence for a two-stage disability progression in multiple sclerosis
Open accessAbstract
It is well documented that disability accumulation in multiple sclerosis is correlated with axonal injury and that the extent of axonal injury is correlated with the degree of inflammation. However, the interdependence between focal inflammation, diffuse inflammation and neurodegeneration, and their relative contribution to clinical deficits, remains ambiguous. A hypothesis might be that early focal inflammation could be the pivotal event from which all else follows, suggesting the consideration of multiple sclerosis as a two-stage disease. This prompted us to define two phases in the disease course of multiple sclerosis by using two scores on the Kurtzke Disability Status Scale as benchmarks of disability accumulation: an early phase, 'Phase 1', from multiple sclerosis clinical onset to irreversible Disability Status Scale 3 and a late phase, 'Phase 2', from irreversible Disability Status Scale 3 to irreversible Disability Status Scale 6. Outcome was assessed through five parameters: Phase 1 duration, age at Disability Status Scale 3, time to Disability Status Scale 6 from multiple sclerosis onset, Phase 2 duration and age at Disability Status Scale 6. The first three were calculated among all patients, while the last two were computed only among patients who had reached Disability Status Scale 3. The possible influence of early clinical markers on these outcomes was studied using Kaplan-Meier estimates and Cox models. The analysis was performed in the Rennes multiple sclerosis database (2054 patients, accounting for 26,273 patient-years) as a whole, and according to phenotype at onset (1609 relapsing/445 progressive onset). Our results indicated that the disability progression during Phase 2 was independent of that during Phase 1. Indeed, the median Phase 2 duration was nearly identical (from 6 to 9 years) irrespective of Phase 1 duration (<3, 3 to <6, 6 to <10, 10 to <15, >or=15 years) in the whole population, and in both phenotypes. In relapsing onset multiple sclerosis, gender, age at onset, residual deficit after the first relapse and relapses during the first 2 years of multiple sclerosis were found to be independent predictive factors of disability progression, but only during Phase 1. Our findings demonstrate that multiple sclerosis disability progression follows a two-stage process, with a first stage probably dependent on focal inflammation and a second stage probably independent of current focal inflammation. This concept has obvious implications for the future therapeutic strategy in multiple sclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
New Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Cited by
Dobson, R., & Giovannoni, G. (2019) · European Journal of Neurology · doi:10.1111/ene.13819 · Cited by 2,148
Progressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis
Lassmann, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03116 · Cited by 663
Multiple sclerosis: clinical aspects
Oh, J., Vidal-Jordana, A., & Montalban, X. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000622 · Cited by 620
Role of the innate and adaptive immune responses in the course of multiple sclerosis
Hemmer, B., Kerschensteiner, M., & Korn, T. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70305-9 · Cited by 584
Defining high, medium, and low impact prognostic factors for developing multiple sclerosis
Tintore, M., Rovira, À., Río, J., Otero-Romero, S., Arrambide, G., Tur, C., Comabella, M., Nos, C., Arévalo, M. J., Negrotto, L., et al. (2015) · Brain · doi:10.1093/brain/awv105 · Cited by 530
Epidemiology of multiple sclerosis
Leray, E., Moreau, T., Fromont, A., & Edan, G. (2016) · Revue Neurologique · doi:10.1016/j.neurol.2015.10.006 · Cited by 478
Self-citationSilent progression in disease activity–free relapsing multiple sclerosis
University of California, S. F. M. T., Cree, B. A. C., Hollenbach, J. A., Bove, R., Kirkish, G., Sacco, S., Caverzasi, E., Bischof, A., Gundel, T., Zhu, A. H., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25463 · Cited by 465
Natural History of Multiple Sclerosis Symptoms
Kister, I., Bacon, T. E., Chamot, E., Salter, A. R., Cutter, G. R., Kalina, J. T., & Herbert, J. (2013) · International Journal of MS Care · doi:10.7224/1537-2073.2012-053 · Cited by 450
Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort
Rotstein, D. L., Healy, B. C., Malik, M. T., Chitnis, T., & Weiner, H. L. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.3537 · Cited by 418
Quantification of increased cellularity during inflammatory demyelination
Wang, Y., Wang, Q., Haldar, J. P., Yeh, F.-C., Xie, M., Sun, P., Tu, T.-W., Trinkaus, K., Klein, R. S., Cross, A. H., et al. (2011) · Brain · doi:10.1093/brain/awr307 · Cited by 384
Luchetti, S., Fransen, N. L., van Eden, C. G., Ramaglia, V., Mason, M., & Huitinga, I. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1818-y · Cited by 355
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
Giovannoni, G., Turner, B., Gnanapavan, S., Offiah, C., Schmierer, K., & Marta, M. (2015) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2015.04.006 · Cited by 338
Onset of secondary progressive phase and long-term evolution of multiple sclerosis
Scalfari, A., Neuhaus, A., Daumer, M., Muraro, P. A., & Ebers, G. C. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304333 · Cited by 291
Age and disability accumulation in multiple sclerosis
Scalfari, A., Neuhaus, A., Daumer, M., Ebers, G. C., & Muraro, P. A. (2011) · Neurology · doi:10.1212/wnl.0b013e318230a17d · Cited by 279
Commowick, O., Istace, A., Kain, M., Laurent, B., Leray, F., Simon, M., Pop, S. C., Girard, P., Améli, R., Ferré, J.-C., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31911-7 · Cited by 277
Self-citationSmouldering multiple sclerosis: the ‘real MS’
Giovannoni, G., Popescu, V., Wuerfel, J., Hellwig, K., Iacobaeus, E., Jensen, M. B., García-Domínguez, J. M., Sousa, L., De Rossi, N., Hupperts, R., et al. (2022) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211066751 · Cited by 271
Ribbons, K. A., McElduff, P., Boz, C., Trojano, M., Izquierdo, G., Duquette, P., Girard, M., Grand’Maison, F., Hupperts, R., Grammond, P., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0122686 · Cited by 190
Microglial autophagy–associated phagocytosis is essential for recovery from neuroinflammation
Berglund, R., Guerreiro-Cacais, A. O., Adzemovic, M. Z., Zeitelhofer, M., Lund, H., Ewing, E., Ruhrmann, S., Nutma, E., Parsa, R., Thessen-Hedreul, M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abb5077 · Cited by 149
Brain modulation by the gut microbiota: From disease to therapy
Mitra, S., Dash, R., Nishan, A. A., Habiba, S. U., & Moon, I. S. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2022.12.001 · Cited by 91
Diagnosis and Management of Progressive Multiple Sclerosis
Macaron, G., & Ontaneda, D. (2019) · Biomedicines · doi:10.3390/biomedicines7030056 · Cited by 70
Köhler, W., Engelen, M., Eichler, F., Lachmann, R., Fatemi, A., Sampson, J., Salsano, E., Gamez, J., Molnar, M. J., Pascual, S., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00495-1 · Cited by 48
Self-reported levels of education and disability progression in multiple sclerosis
D'hooghe, M. B., Haentjens, P., Van Remoortel, A., De Keyser, J., & Nagels, G. (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12555 · Cited by 35
Martin, N. A., Nawrocki, A., Molnar, V., Elkjaer, M. L., Thygesen, E. K., Palkovits, M., Acs, P., Sejbaek, T., Nielsen, H. H., Hegedus, Z., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0202530 · Cited by 29
Omura, S., Sato, F., Martinez, N. E., Park, A.-M., Fujita, M., Kennett, N. J., Cvek, U., Minagar, A., Alexander, J. S., & Tsunoda, I. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00516 · Cited by 20
Brieva, L., Calles, C., Landete, L., & Oreja-Guevara, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1543649 · Cited by 16
De Masi, R., Orlando, S., & De Donno, A. (2021) · Pharmaceuticals · doi:10.3390/ph14020081 · Cited by 5
Metadata
- Authors
- Leray, E., Yaouanq, J., Le Page, E., Coustans, M., Laplaud, D., Oger, J., & Edan, G.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-04-27
- Volume
- 133
- Issue
- 7
- Pages
- 1900-1913
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2171100984
- Cited by
- 596
- References
- 54
- FWCI
- 17.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.